# Delayed recovery following myasthenic exacerbation and subsequent endplate-protecting treatment

**Authors:** Anna Mück, Sonja Genau, Julia Emde, Christoph Best, Steffen Pfeuffer, Heidrun H. Krämer

PMC · DOI: 10.1007/s10072-025-08617-6 · Neurological Sciences · 2026-02-04

## TL;DR

This paper shows that recovery from a myasthenia gravis flare-up takes about nine months even with endplate-protecting treatments.

## Contribution

The study provides new evidence on the prolonged recovery time following myasthenic exacerbation despite endplate-protecting therapies.

## Key findings

- Seven out of 12 patients with myasthenic exacerbation received endplate-protecting therapies.
- Acceptable recovery after treatment typically takes about nine months.
- The results suggest that new treatments for myasthenia should be evaluated over longer observation periods.

## Abstract

Endplate-protecting therapies have improved treatment of myasthenia gravis and indicate a rapid onset of their treatment effect. Currently, these substances can be used following myasthenic exacerbation (ME). Clinical worsening due to ME however often results in prolonged recovery. We here evaluated the treatment courses of patients having received endplate-protecting treatment following ME. Among 12 patients with ME described here, seven received endplate-protecting therapies. Our findings indicate that acceptable recovery usually takes nine months. In the lights of recent trials for treatment of myasthenia, our findings implicate that the effectiveness of novel substances should be judged only after sufficient observation periods.

## Linked entities

- **Diseases:** myasthenia gravis (MONDO:0009688)

## Full-text entities

- **Genes:** FCGRT (Fc gamma receptor and transporter) [NCBI Gene 2217] {aka FCRN, FcgammaRn, alpha-chain}, TTN (titin) [NCBI Gene 7273] {aka CMD1G, CMH9, CMPD4, CMYO5, CMYP5, EOMFC}, MUSK (muscle associated receptor tyrosine kinase) [NCBI Gene 4593] {aka CMS9, FADS}, LRP4 (LDL receptor related protein 4) [NCBI Gene 4038] {aka CLSS, CMS17, LRP-4, LRP10, MEGF7, SOST2}, SOX1 (SRY-box transcription factor 1) [NCBI Gene 6656]
- **Diseases:** MG (MESH:D009157), infection (MESH:D007239), EPT (MESH:C566415), PASS (MESH:D012816), respiratory insufficiency (MESH:D012131), disability (MESH:D009069), seropositive (MESH:D006679), SOC (MESH:D003428), COVID-19 (MESH:D000086382), influenza (MESH:D007251), thymoma (MESH:D013945), myasthenia (MESH:D020294), bacterial pneumonia (MESH:D018410), ME (MESH:D018450)
- **Chemicals:** ravulizumab (MESH:C000629409), prednisolone (MESH:D011239), PYR (MESH:D009242), cyclophosphamide (MESH:D003520), MMF (MESH:D009173), C5 inhibitors (-), Alexion (MESH:C481642), SoC (MESH:C001599), AZA (MESH:D001379), DMT (MESH:D004130), pyridostigmine (MESH:D011729), steroid (MESH:D013256), efgartigimod alfa (MESH:C000718373), MTX (MESH:D008727)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12868007/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12868007/full.md

---
Source: https://tomesphere.com/paper/PMC12868007